Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD5 CAR-NK cells
- Development stage
- Unknown
- Lead developer
- Hospital Clínic de Barcelona
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD5 CAR-NK cells (SRCD5CAR-NK) is an investigational adoptive cellular immunotherapy developed by Fundació de Recerca Clínic Barcelona-IDIBAPS for the treatment of refractory invasive mold disease (IMD). Unlike conventional CAR-NK therapies that target the CD5 antigen on malignant T cells, this construct utilizes the extracellular domain of the human CD5 scavenger receptor as the antigen-binding component of the chimeric antigen receptor. This allows the NK cells to leverage the natural β-glucan-binding properties of CD5 to recognize and attack fungal cell wall components. Preclinical studies have demonstrated its efficacy against various pathogenic fungi, including *Aspergillus*, *Candida*, *Cryptococcus*, and *Fusarium* species. It is currently being evaluated in a Phase 1 first-in-human clinical trial.
- Other names
- CD5CAR-NK cellsCD-5CAR-NK cellsCD 5CAR-NK cells
02
Targets
β-glucan (Beta-glucan)
Beyond the preview
Go deeper on CD5 CAR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD5 CAR-NK cells.